Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kochenderfer Website

James N. Kochenderfer, M.D.

Selected Publications

1)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-60, 2013.
2)  Kochenderfer JN, Rosenberg SA.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Nat Rev Clin Oncol. 10: 267-76, 2013.
3)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
4)  Kochenderfer JN, Rosenberg SA.
Chimeric antigen receptor-modified T cells in CLL.
N. Engl. J. Med. 365: 1937-8; author reply 1938, 2011.
5)  Rosenberg SA, Kochenderfer JN.
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.
Mol. Ther. 19: 1928-30, 2011.
6)  Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA.
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a.
Hum. Gene Ther. 22: 107-15, 2011.
7)  Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Blood. 116: 3875-86, 2010.
8)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Blood. 116: 4099-102, 2010.
9)  Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA.
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
J. Immunol. 183: 5563-74, 2009.
10)  Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
J. Immunother. 32: 689-702, 2009.
11)  Kochenderfer JN, Gress RE.
A comparison and critical analysis of preclinical anticancer vaccination strategies.
Exp. Biol. Med. (Maywood). 232: 1130-41, 2007.
12)  Kochenderfer JN, Chien CD, Simpson JL, Gress RE.
Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.
Clin. Immunol. 124: 119-30, 2007.
13)  Kochenderfer JN, Simpson JL, Chien CD, Gress RE.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.
Blood. 110: 450-60, 2007.
14)  Kochenderfer JN, Chien CD, Simpson JL, Gress RE.
Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses.
J. Immunol. 177: 8860-73, 2006.
15)  Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ.
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.
Blood. 100: 3639-45, 2002.
16)  Kochenderfer JN, Molldrem JJ.
Leukemia vaccines.
Curr Oncol Rep. 3: 193-200, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/6/2013.